G Toteda1, S Lupinacci1, D Vizza1, R Bonofiglio1, E Perri2, M Bonofiglio1, D Lofaro1, A La Russa1, F Leone1, P Gigliotti1, R A Cifarelli3, A Perri4. 1. "Kidney and Transplantation" Research Center, UOC Nephrology, Dialysis and Transplantation, Annunziata Hospital, F. Migliori, 1, 87100, Cosenza, CS, Italy. 2. Consiglio per la Ricerca in Agricoltura e l'Analisi dell'Economia Agraria (CREA)-Olive Growing and Olive Oil Industry Research Centre, Rende, CS, Italy. 3. Laboratory X-life, ARPAB-CRM, Matera Hospital, Matera, Italy. 4. "Kidney and Transplantation" Research Center, UOC Nephrology, Dialysis and Transplantation, Annunziata Hospital, F. Migliori, 1, 87100, Cosenza, CS, Italy. anna_perri@yahoo.it.
Abstract
PURPOSE: Recent evidences indicates that hydroxytyrosol, one of the main olive oil phenols, possess antitumor effects because of its pro-oxidant properties and the capacity to inhibit proliferation and to promote apoptosis in several tumor cell lines, although most of the results were obtained for breast and digestive systems cancers. METHODS: In this study, we evaluated the activities of hydroxytyrosol against papillary (TPC-1, FB-2) and follicular (WRO) thyroid cancer cell lines. RESULTS: Cellular viability revealed that high doses of hydroxytyrosol reduced cancer cells viability concomitantly with a reduction of cyclin D1 expression and an up-regulation of cell cycle key modulator p21 levels. In the same experimental conditions, Annexin V-PI staining and DNA laddering revealed that hydroxytyrosol exerts proapoptotic effects on papillary and follicular cancer cells. Furthermore, by Western blot analysis, we observed that hydroxytyrosol treatment reduced thyroid cancer cells viability by promoting apoptotic cell death via intrinsic pathway. CONCLUSIONS: Collectively, our results demonstrated for the first time that in thyroid cancer cells hydroxytyrosol promoted apoptosis at higher doses with respect to other cancer cells lines. Therefore, further studies will reveal the mechanisms by which thyroid cancer cells are more resistant to the proapoptotic effect exerted by hydroxytyrosol as well as the potential application as novel target therapeutic in thyroid cancer.
PURPOSE: Recent evidences indicates that hydroxytyrosol, one of the main olive oil phenols, possess antitumor effects because of its pro-oxidant properties and the capacity to inhibit proliferation and to promote apoptosis in several tumor cell lines, although most of the results were obtained for breast and digestive systems cancers. METHODS: In this study, we evaluated the activities of hydroxytyrosol against papillary (TPC-1, FB-2) and follicular (WRO) thyroid cancer cell lines. RESULTS: Cellular viability revealed that high doses of hydroxytyrosol reduced cancer cells viability concomitantly with a reduction of cyclin D1 expression and an up-regulation of cell cycle key modulator p21 levels. In the same experimental conditions, Annexin V-PI staining and DNA laddering revealed that hydroxytyrosol exerts proapoptotic effects on papillary and follicular cancer cells. Furthermore, by Western blot analysis, we observed that hydroxytyrosol treatment reduced thyroid cancer cells viability by promoting apoptotic cell death via intrinsic pathway. CONCLUSIONS: Collectively, our results demonstrated for the first time that in thyroid cancer cells hydroxytyrosol promoted apoptosis at higher doses with respect to other cancer cells lines. Therefore, further studies will reveal the mechanisms by which thyroid cancer cells are more resistant to the proapoptotic effect exerted by hydroxytyrosol as well as the potential application as novel target therapeutic in thyroid cancer.
Entities:
Keywords:
Apoptosis; Hydroxytyrosol; Nutrition; Olive oil; Thyroid cancer
Authors: F Della Ragione; V Cucciolla; A Borriello; V Della Pietra; C Manna; P Galletti; V Zappia Journal: Biochem Biophys Res Commun Date: 2000-02-24 Impact factor: 3.575
Authors: M Servili; S Esposto; R Fabiani; S Urbani; A Taticchi; F Mariucci; R Selvaggini; G F Montedoro Journal: Inflammopharmacology Date: 2009-04 Impact factor: 4.473
Authors: Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen Journal: J Clin Endocrinol Metab Date: 2008-08-19 Impact factor: 5.958
Authors: Franclim Ricardo Ribeiro; Ana Margarida Meireles; Ana Sofia Rocha; Manuel Rodrigues Teixeira Journal: BMC Cancer Date: 2008-12-16 Impact factor: 4.430
Authors: S Lupinacci; G Toteda; D Vizza; A Perri; C Benincasa; A Mollica; A La Russa; P Gigliotti; F Leone; D Lofaro; M Bonofiglio; E Perri; R Bonofiglio Journal: J Nephrol Date: 2016-12-02 Impact factor: 3.902
Authors: José J Gaforio; Francesco Visioli; Catalina Alarcón-de-la-Lastra; Olga Castañer; Miguel Delgado-Rodríguez; Monserrat Fitó; Antonio F Hernández; Jesús R Huertas; Miguel A Martínez-González; Javier A Menendez; Jesús de la Osada; Angeliki Papadaki; Tesifón Parrón; Jorge E Pereira; María A Rosillo; Cristina Sánchez-Quesada; Lukas Schwingshackl; Estefanía Toledo; Aristidis M Tsatsakis Journal: Nutrients Date: 2019-09-01 Impact factor: 5.717
Authors: Saad Al Fazazi; Rafael A Casuso; Jerónimo Aragón-Vela; Cristina Casals; Jesús R Huertas Journal: J Int Soc Sports Nutr Date: 2018-04-27 Impact factor: 5.150